Biodexa Pharmaceuticals
BDRX
3 hedge funds and large institutions have $31.2K invested in Biodexa Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
25% less funds holding
Funds holding: 4 → 3 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
82% less capital invested
Capital invested by funds: $169K → $31.2K (-$138K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GI
GAMMA Investing
Foster City,
California
|
+$15.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$120K |
| 2 |
Renaissance Technologies
New York
|
-$31K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GI
1
GAMMA Investing
Foster City,
California
| $18K | +$15.8K | +8 | +800% |
|
2
Bank of America
Charlotte,
North Carolina
| $8.48K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $3.95K | +$3.96K | +2 | New |
|
4
RhumbLine Advisers
Boston,
Massachusetts
| $806 | – | – | – |
|
5
Morgan Stanley
New York
| $26 | – | – | – |
|
|
BFM
6
Boothbay Fund Management
New York
| – | -$120K | -36 | Closed |
|
|
7
Renaissance Technologies
New York
| – | -$31K | -9 | Closed |
|
BDRX Hedge Fund Activity: Q1 2024 in Review
3 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q1 2024, worth a combined $31.2K — down 82% from $169K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BDRX and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was GAMMA Investing, adding an estimated $15.8K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $120K sold.
- 3 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q1 2024, down from 4 in Q4 2023.
- Funds reported $31.2K of Biodexa Pharmaceuticals stock for Q1 2024, down 82% quarter-over-quarter.
- 1 fund opened new Biodexa Pharmaceuticals positions in Q1 2024 and 2 closed out, a net change of -1 holder.
- The largest Biodexa Pharmaceuticals buyer in Q1 2024 was GAMMA Investing, an estimated $15.8K added.
- The largest Biodexa Pharmaceuticals seller in Q1 2024 was Boothbay Fund Management, an estimated $120K sold.
Based on aggregated 13F filings for Q1 2024.